Conmed (CNMD) Tops Q3 EPS by 5c

Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.44, $0.05 better than the analyst estimate of $0.39. Revenue for the quarter came in at $175 million versus the consensus estimate of $173.3 million.

Conmed sees FY2014 EPS of $1.85-$1.95, versus the consensus of $1.87.

"We are pleased with our results for the quarter, which keep us on track to deliver on our full year revised revenue and earnings commitments. 2014 has been a challenging year in which CONMED has undergone some significant changes. We are working diligently to enhance fundamental strengths of our business to reestablish top line growth while continuing to deliver leveraged earnings growth," commented Curt R. Hartman, Interim Chief Executive Officer. "We thank our shareholders and employees alike who have shared important ideas focused on value creation for all CONMED stakeholders."

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance